Marco Meglio

During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around.

The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.

Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.

Women with migraine with cold extremities had higher attack frequencies, which data suggest stems partly from sleep disturbances.

The wide variance in onabotunlinumtoxinA use for migraine prevention raises the question of whether evidence-based advisory statements might be more helpful than a proscriptive protocol.

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

The first study to assess the effect of endovascular therapy added on to intravenous thrombolysis uncovered more evidence of its effect on specific occlusions rather than overall outcomes.

Early treatment with Ionis Pharmaceuticals’s inotersen resulted in greater long-term disease stabilization than delayed initiation.

Data led the authors to believe that vitamin D might have neuroprotective properties and that levels may be a prognostic marker of long-term cognition and neuroaxonal integrity.

The exercise and physical activity recommendations were tailored to individuals with differing disability levels on the Expanded Disability Status Scale.

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

Banner Life Science’s novel fumarate bioequivalent alternative to Tecfidera (dimethyl fumarate; Biogen) enters the market as a new oral treatment option for relapsing forms of multiple sclerosis.

An emphasis on at-home care as well as reducing the risk of seizure exacerbation are among a list of notable recommendations to help optimize clinical care for patients with epilepsy amidst the COVID-19 pandemic.

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.

The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.

The Rosenthal–Trotter MS Chair in Neuroimmunology at Washington University School of Medicine in St. Louis details why the COViMS registry can serve as an important instrument for clinicians who treat patients with multiple sclerosis.

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.

Exclusive breastfeeding may be recommended after it was shown to reduce the risk of postpartum relapses.

Cumulative mean systolic blood pressure was associated with those faster declines in memory which were significantly more common in black individuals than white individuals.